There are currently no plans to do so, but the Centers for Disease Control and Prevention and the American Academy of Pediatrics are discussing the issue with physicians, said Dr. Robert Shiller, director of the University of Michigan’s Center for Health Policy and Economics.
The issue is being considered by both the CDC and the AMA, Shiller said.
He said there are concerns about how quickly these drugs could become available.
“A large part of this is due to the fact that there’s not been a full study on the efficacy and safety of this new drug, so it’s not known if this will be a safe treatment for all patients or whether it will work at lower doses,” Shiller told FoxNews.com.
Shiller said the AMA is working with the CDC to develop a roadmap for how to best manage this new treatment.
The CDC is already in discussions with drugmakers about developing new drugs for patients with severe EHD.
The CDC is also planning to create a national registry for EHD patients to monitor the drug’s safety and efficacy, Shilling said.
The AMA is also exploring a drug called EpiDot for patients at high risk of severe EH.
The drug is not approved for use in the United States and could be expensive, according to Shiller.
“It is important that we take the best available science into account, and we need to ensure that the best science is applied to the clinical use of the drug,” Shilling wrote in a statement.
Dr. Robert Blanchard, president of the American College of Cardiology, also criticized the new EHD drugs as too soon.
“We have an unprecedented amount of EHD, and it has taken a long time for us to have this kind of data about this new class of drugs,” Blanchar wrote in an email to FoxNews, citing data from the American Heart Association that showed that patients with moderate to severe EHH are more likely to require dialysis, which is a more expensive option than dialysis itself.
“If we’re not looking at these drugs in the right way, we’re going to be putting a lot of patients at risk.”
The new drugs are also being tested for side effects, but there are no known risks to people taking them, according the CDC.
The drugs are currently available in clinical trials for patients who have severe EHS and severe depression, but doctors have yet to see a clear safety benefit for patients taking the drugs.
The American College is also looking at the efficacy of the drugs and whether they are effective for people with milder forms of EH and depression, said Shiller.
“These are exciting times for patient care and for the medical community,” said Blancher.
“But the time has come to take the drug safety and patient safety concerns into account.”